AI tool helps to diagnose and predict severity of lung cancers

Breaking barriers in lung cancer research

The fight against lung cancer is evolving, with groundbreaking research shedding light on the intricate interplay between biology, environment, and health disparities.

September 12, 2025

Vol.51 No.33

By Loretta Erhunmwunsee

Obituary

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Bonnie J. Addario, a tireless advocate, died Aug. 25, leaving behind a legacy of love, leadership, and global impact. Bonnie was first and foremost devoted to her family—her husband of over 40 years, Tony; her children Danielle, Jared, and Andrea; her nine grandchildren; and five great-grandchildren. To all of them, she was the heart of...

September 12, 2025

Vol.51 No.33

By Neptune Society

In Brief

Anirban Maitra, Manuel Hidalgo, join NYU Langone new GI cancer center as co-directors

Anirban MaitraManuel HidalgoAnirban Maitra and Manuel Hidalgo were named co-directors of a new Gastrointestinal Cancer Center at NYU Langone Health’s Perlmutter Cancer Center.

September 12, 2025

Vol.51 No.33

In Brief

Montefiore Einstein’s lung cancer team earns international recognition

Montefiore Einstein CCC lung cancer teamMontefiore Einstein Comprehensive Cancer Center’s lung cancer team received the The Cancer Care Team Award from the International Association for the Study of Lung Cancer.

September 12, 2025

Vol.51 No.33

In Brief

Northwestern Medicine to adopt “David,” a generative AI copilot by Tempus AI Inc.

Northwestern Medicine will be the first health system to integrate “David,” Tempus’ generative-AI clinical co-pilot, within its electronic health record platform for its clinical care team.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.

September 12, 2025

Vol.51 No.33

AI tool helps to diagnose and predict severity of lung cancers

YOU MAY BE INTERESTED IN

Breaking barriers in lung cancer research

Bonnie Addario, lung cancer survivor and advocate, dies at 77

Anirban Maitra, Manuel Hidalgo, join NYU Langone new GI cancer center as co-directors

Montefiore Einstein’s lung cancer team earns international recognition

Northwestern Medicine to adopt “David,” a generative AI copilot by Tempus AI Inc.

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login